NCT03148327 - Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 11, 2017

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Durvalumab (MEDI 4736)

Early studies has shown to possibly reduce the growth of certain types of lung cancer

RADIATION

Radiotherapy

Stereotactic Body Radiation Therapy (SABR)

Trial Locations (4)

Peter MacCallum Cancer Centre, Melbourne E.

New York Weill Cornell Cancer Center at Cornell University, New York

Jonsson Comprehensieve Cancer Center, Los Angeles

University of Colorado, Denver